<DOC>
	<DOCNO>NCT01362062</DOCNO>
	<brief_summary>This observational study evaluate safety , tolerability efficacy tocilizumab participant moderate severe RA inadequate response current non-biologic DMARD and/or anti-TNF therapy . Data collect participant tocilizumab therapy follow-up total 12 month .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Efficacy Tocilizumab Participants With Rheumatoid Arthritis ( RA ) Who Have Inadequate Response Non-Biologic Disease Modifying Anti-rheumatic Drugs ( DMARDs ) and/or Anti-tumor Necrosis Factor ( Anti-TNF ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Moderate severe active RA inadequate response exist therapy ( DMARDs and/or antiTNFs ) Considered eligible tocilizumab therapy treat physician per routine clinical practice Pregnant breastfeeding female Immunization live/attenuated vaccine within 4 week prior baseline Participants clinically significant raise liver enzyme , abnormal lipid profile , platelet count , hemoglobin , white blood cell neutrophil count History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Participants active tuberculosis ( TB ) . Participants latent TB treat standard antimycobacterial therapy initiate tocilizumab negative chest x ray active TB enrolment History diverticulitis , chronic ulcerative low GI disease Crohn 's disease , ulcerative colitis symptomatic low GI condition might predispose perforation benefit risk ratio consider treat physician Know active current history recurrent bacterial , viral , fungal , mycobacterial infection History currently active primary secondary immunodeficiency know human immunodeficiency virus ( HIV ) positive status Any condition put participant undue risk tocilizumab therapy per local prescribe information Investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>